Journal
VACCINES
Volume 9, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9121475
Keywords
breastmilk; immunization (vaccination); SARS-CoV-2; immunoglobulin A; BNT162b2 mRNA COVID-19 vaccine; COVID-19
Categories
Funding
- Stichting Steun Emma Kinderziekenhuis
- Amsterdam Infection and Immunity Institute [24175]
- [COVID-19]
Ask authors/readers for more resources
This study found that the levels of SARS-CoV-2-specific antibodies in breast milk were similar after vaccination or infection. There was higher variability in IgA levels in breast milk following infection compared to vaccination.
SARS-CoV-2-specific antibodies are secreted into human milk of infected or vaccinated lactating women and might provide protection to the breastfed infant against COVID-19. Differences in antibody response after these types of exposure are unknown. In this longitudinal cohort study, we compared the antibody response in human milk following SARS-CoV-2 vaccination or infection. We analyzed 448 human milk samples of 28 lactating women vaccinated with the SARS-CoV-2 vaccine BNT162b2 as well as 82 human milk samples of 18 lactating women with a prior SARS-CoV-2 infection. The levels of SARS-CoV-2-specific IgA in human milk were determined over a period of 70 days both after vaccination and infection. The amount of SARS-CoV-2-specific IgA in human milk was similar after SARS-CoV-2 vaccination and infection. After infection, the variability in IgA levels was higher than after vaccination. Two participants with detectable IgA prior to vaccination were analyzed separately and showed higher IgA levels following vaccination compared to both groups. In conclusion, breastfed infants of mothers who have been vaccinated with the BNT162b2 vaccine receive human milk with similar amounts of SARS-CoV-2-specific antibodies compared to infants of previously infected mothers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available